Antithrombin deficiency (ATD) in pregnant patients significantly increases the risk of venous thromboembolism (VTE), but guidelines for managing anticoagulation during pregnancy, labour, and postpartum in patients with ATD are limited. A pregnant woman with ATD suffered recurrent VTE in the 20th week of pregnancy despite therapeutic doses of low-molecular-weight heparin (LMWH). The acute VTE was treated with argatroban and then with warfarin until delivery. LMWH with antithrombin (AT) concentrate was introduced before and shortly after delivery, followed by warfarin, which was continued also postpartum. No further complications occurred during the remainder of pregnancy, delivery, and two-year follow-up. Our case highlights the challenges of anticoagulant treatment in pregnant patients with ATD. Standard weight-based LMWH dosing can lead to inadequate anticoagulation, as demonstrated by an acute VTE event in our patient. In our case, the use of argatroban proved to be safe and effective in the acute setting, followed by warfarin in the 2nd and 3rd trimester, and subsequent co-administration of LMWH and AT concentrate before and after delivery. Concomitant use of LMWH and AT concentrate allows for achieving target anti-Xa levels. Measurement of both anti-Xa and AT activity is advisable in this scenario to ensure reliable anticoagulant management. ATD is a heterogeneous disorder; therefore, each successfully managed pregnancy advances clinical practice.
6 November 2026 in Journal of Cardiovascular Pharmacology and Therapeutics
Background: Cardiovascular diseases remain the leading cause of mortality worldwide, with elevated low-density lipoprotein cholesterol representing a major risk factor. Rosuvastatin is widely used for cardiovascular prevention due to its potent lipid-lowering effects. Significant interindividual variability exists in its pharmacokinetics (PK), pharmacodynamic (PD) response, and susceptibility to adverse effects, which is not fully understood. Objective: Genome-wide association studies (GWAS) and exome-wide association studies (ExWAS) have emerged as powerful approaches to identify genetic determinants that influence drug response. This review aimed to summarize evidence from such studies investigating the influence of genetic variation on rosuvastatin PK, PD, and intolerance. Design: A systematic literature search was performed in PubMed and Web of Science to identify GWAS and ExWAS studies examining associations between single-nucleotide polymorphisms (SNPs) and rosuvastatin PK, PD, or intolerance. Eligible English-language studies published up to July, 2025 were independently screened by two reviewers, and data were extracted from the included studies. Results: Six eligible studies were included, and relevant data were extracted. Genome-wide significant associations were observed for SLCO1B1 , affecting rosuvastatin plasma concentrations, while variants in ABCG2, LPA, APOE , and PCSK9 were linked to PD effects. Common variants in TMEM9 and KLF12 were associated with rosuvastatin intolerance. Additional SNPs were identified at sub-genome-wide or exome-wide significance levels. Conclusion: Limitations across studies included treatment with different statins and small sample sizes, which may obscure conclusions. Overall, these findings highlight the potential of pharmacogenomic research to guide personalized rosuvastatin therapy by identifying individuals at higher risk of altered drug response or adverse events.
Background: Diagnosis of antithrombin deficiency (ATD), the most severe inherited thrombophilia, commonly relies on functional assays despite their uncertain sensitivity. Moreover, routine characterization of ATD remains uncommon due to limited supporting clinical data. Objectives: This study aimed to evaluate the diagnostic sensitivity of commercial antithrombin (AT) activity assays and assess clinical differences among ATD types to refine the current diagnostic approach. Methods: Eighty-eight patients with decreased AT activity and 124 consecutive patients with unprovoked venous thromboembolism were included. AT activity was measured using six assays. Genetic analysis of SERPINC1 was performed by Sanger sequencing and multiplex ligation-dependent probe amplification; additionally, long-read whole-genome sequencing was conducted. Results: Fifteen SERPINC1 variants were detected, including two novel ones. AT Padua I (p.Arg79His) was the most prevalent (49%). Sensitivity varied across AT activity assays, particularly for types IIRS and IIHBS, with variant-specific discrepancies. AT Dublin (p.Val30Glu), causing transient deficiency, was undetected by all assays. Two assays demonstrated very high sensitivity (93%; p<0.001), while two others showed poor sensitivity (46%). Regardless of measured AT activity, characterization of ATD type enabled better risk stratification. Type I was associated with early-onset and recurrent venous thromboembolism, and type IIHBS was distinctly linked to arterial thrombosis. Conclusions: Assay sensitivity varies considerably, and only a few proved suitable as first-line tests. Genetic testing for common variants undetectable by even the most sensitive assays, along with ATD characterization, should be integrated into diagnostic algorithms. Our results also suggest that young patients with arterial thrombosis should be screened for ATD.